David A. Zarling PhD, MBA

David Zarling PhD MBA is a Founder and the CEO of Colby Pharmaceutical Company Menlo Park, California, and is leading the commercialization of IntraLymphNode Immunotherapeutics (CILNI™) and immunoactivating biological agents for cancer and other patients. David successfully managed the Colby team in the sale of three of their late pre-clinical or early clinical anti-cancer drugs and in Colby’s subsequent acquisition of Othera Pharmaceuticals with anti-inflammatory and anti-cancer clinical small molecule pharmaceutical drugs and drug candidates. David also successfully negotiated the world-wide exclusive license from MannKind Corporation to their immuno-therapeutics portfolio (including the technologies and products of CTL ImmunoTherapies and AlleCure Corporation), which are integral to the Colby immunotherapeutic and immunoactivating products.